# Outpatient treatment with concomitant vaccine-boosted convalescent plasma for patients with immunosuppression and COVID-19

Juan G. Ripoll<sup>1\*</sup>, MD, Sidna M. Tulledge-Scheitel<sup>2\*</sup>, MD, MPH, Anthony A. Stephenson<sup>1</sup>, MD, Shane Ford<sup>1</sup>, BS, Marsha L. Pike<sup>3</sup>, APRN, CNS, DNP, Ellen K. Gorman<sup>1</sup>, BS, Sara N. Hanson<sup>4</sup>, DO, MPH, Justin E. Juskewitch<sup>5</sup>, MD, PhD, Alex J. Miller<sup>1</sup>, BS, Solomiia Zaremba<sup>1</sup>, MD, Erik A. Ovrom<sup>1</sup>, BA, Raymund R. Razonable<sup>6</sup>, MD, Ravindra Ganesh<sup>7</sup>, MBBS, MD, Ryan T. Hurt<sup>7</sup>, MD, PhD, Erin N.

Fischer<sup>3</sup>, MS, RN, Amber N. Derr<sup>8</sup>, MBA, Michele R. Eberle<sup>9</sup>, Jennifer J. Larsen<sup>8</sup>, MSN, RN, Christina M. Carney<sup>10</sup>, APRN, CNP, DNP, Elitza S. Theel<sup>5</sup>, PhD, Sameer A. Parikh<sup>11</sup>, MBBS, Neil E.

Kay<sup>11,12</sup>, MD, Michael J. Joyner<sup>1,13†</sup>, MD, and Jonathon W. Senefeld<sup>1,13,14</sup><sup>1/2</sup><sup>+</sup>, PhD

### AFFILIATIONS

**1** | Department of Anesthesiology and Perioperative Medicine, Mayo Clinic, Rochester, Minnesota

2 | Division of Community Internal Medicine, Mayo Clinic, Rochester, Minnesota

**3** | Department of Nursing, Mayo Clinic, Rochester, Minnesota

4 | Department of Family Medicine, Mayo Clinic Health Care System, Mankato, Minnesota

5 | Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota

**6** | Division of Public Health, Infectious Diseases, and Occupational Medicine, Mayo Clinic, Rochester, Minnesota

7 | Division of General Internal Medicine, Mayo Clinic, Rochester, Minnesota

8 | Division of Hematology and Infusion Therapy, Rochester, Minnesota, USA

9 | Mayo Clinic Health System Northwest Wisconsin, Eau Claire, Wisconsin, USA

10 | Mayo Clinic Health System, Red Wing, Minnesota,

11 | Division of Hematology, Mayo Clinic, Rochester, Minnesota

12 | Department of Immunology, Mayo Clinic, Rochester, Minnesota

**13** | Department of Physiology and Biomedical Engineering, Mayo Clinic, Rochester, Minnesota

**14** | Department of Health and Kinesiology, University of Illinois at Urbana-Champaign, Urbana, Illinois

#### <sup>2</sup>Correspondence:

Jonathon W. Senefeld, PhD, Department of Health and Kinesiology University of Illinois Urbana-Champaign | 906 S Goodwin | Urbana, Illinois 61801 senefeld@illinois.edu | 217-300-7991

<sup>\*</sup>Dr. Ripoll and Dr. Tulledge-Scheitel contributed equally as first authors to the work of the study and manuscript.

<sup>†</sup>Drs. Joyner and Senefeld contributed equally as senior authors to the work of the study and manuscript.

#### 1 ABSTRACT

2 Although severe coronavirus disease 2019 (COVID-19) and hospitalization associated with 3 COVID-19 are generally preventable among healthy vaccine recipients, patients with 4 immunosuppression have poor immunogenic responses to COVID-19 vaccines and remain at 5 high risk of infection with SARS-CoV-2 and hospitalization. Additionally, monoclonal antibody 6 therapy is limited by the emergence of novel SARS-CoV-2 variants that have serially escaped 7 neutralization. In this context, there is interest in understanding the clinical benefit associated 8 with COVID-19 convalescent plasma collected from persons who have been both naturally 9 infected with SARS-CoV-2 and vaccinated against SARS-CoV-2 ("vax-plasma"). Thus, we report 10 the clinical outcome of 386 immunocompromised outpatients who were diagnosed with COVID-19 and who received contemporary COVID-19 specific therapeutics (standard of care 11 group) and a subgroup who also received concomitant treatment with very high titer COVID-19 12 13 convalescent plasma (vax-plasma group) with a specific focus on hospitalization rates. The 14 overall hospitalization rate was 2.2% (5 of 225 patients) in the vax-plasma group and 6.2% (10 15 of 161 patients) in the standard of care group, which corresponded to a relative risk reduction of 65% (P=0.046). Evidence of efficacy in nonvaccinated patients cannot be inferred from these 16 17 data because 94% (361 of 386 patients) of patients were vaccinated. In vaccinated patients with immunosuppression and COVID-19, the addition of vax-plasma or very high titer COVID-19 18 19 convalescent plasma to COVID-19 specific therapies reduced the risk of disease progression 20 leading to hospitalization.

#### 21 **IMPORTANCE**

As SARS-CoV-2 evolves, new variants of concern (VOCs) have emerged which evade available 22 23 anti-spike monoclonal antibodies, particularly among immunosuppressed patients. However, 24 high-titer COVID-19 convalescent plasma continues to be effective against VOCs because of its 25 broad-spectrum immunomodulatory properties. Thus, we report clinical outcomes of 386 26 immunocompromised outpatients who were treated with COVID-19 specific therapeutics and a 27 subgroup also treated with vaccine-boosted convalescent plasma. We found that administration of vaccine-boosted convalescent plasma was associated with a significantly 28 29 decreased incidence of hospitalization among immunocompromised COVID-19 outpatients. Our 30 data add to the contemporary data providing evidence to support the clinical utility of high-titer convalescent plasma as antibody replacement therapy in immunocompromised patients. 31

#### 32 Introduction

Although severe coronavirus disease 2019 (COVID-19) and hospitalization associated with 33 34 COVID-19 are generally preventable among healthy vaccine recipients, patients with immunosuppression have poor immunogenic responses to COVID-19 vaccines and remain at 35 high risk of infection with SARS-CoV-2 and hospitalization.<sup>1,2</sup> Passive antibody therapy, via 36 monoclonal antibody therapy or COVID-19 convalescent plasma, has been widely used to treat 37 COVID-19, particularly among patients with immunosuppression.<sup>3-5</sup> For example, in the 38 outpatient setting, therapeutic use of neutralizing antispike monoclonal antibody has been 39 associated with decreases in the incidence of COVID-19-related disease progression and 40 hospitalization.<sup>6</sup> However, monoclonal antibody therapy is limited by the emergence of novel 41 SARS-CoV-2 variants that have serially escaped neutralization.<sup>7,8</sup> Thus, although monoclonal 42 43 antibody therapy as a cornerstone of COVID-19 treatment, at the time of this writing, there are no US FDA approved monoclonal antibodies for the treatment or prevention of SARS-CoV-2 44 45 infection.<sup>6</sup> However, high-titer COVID-19 convalescent plasma continues to be effective against SARS-CoV-2 variants of concern (VOCs) because of its broad-spectrum immunomodulatory 46 properties and ability to neutralize multiple SARS-CoV-2 variants.<sup>9,10</sup> Although COVID-19 47 convalescent plasma is authorized for therapeutic use among patients with 48 immunosuppression in the US and recommended by some organizations<sup>11,12</sup>, its use remains 49 controversial.<sup>4</sup> 50

COVID-19 convalescent plasma collected from persons who have been both naturally infected 51 with SARS-CoV-2 and vaccinated against SARS-CoV-2 (herein referred to as "vax-plasma" and 52 53 also known as vaccine-boosted convalescent plasma) is particularly high titer, typically containing 10 to 100 times higher anti-SARS-CoV-2 antibody titers than standard COVID-19 54 convalescent plasma.<sup>13-17</sup> To further our understanding of the clinical impact associated with 55 vax-plasma, we report the clinical outcome of 386 immunocompromised outpatients who were 56 diagnosed with COVID-19 and treated with contemporary COVID-19 specific therapeutics 57 (standard of care group) and a subgroup who also received treatment with vax-plasma or high-58 titer COVID-19 convalescent plasma and (vax-plasma group) with a specific focus on 59 60 hospitalization rates.

#### 61 Study design

This large, observational cohort study included data from a single health system (Mayo Clinic) and represented data from multiple health care sites across Minnesota and Wisconsin from 1 December 2022 to 1 December 2023. Immunocompromised patients with active COVID-19 infection, confirmed by SARS-CoV-2-specific reverse transcription polymerase chain reaction, were eligible to receive vax-plasma. The Mayo Clinic Institutional Review Board determined

that this study met the criteria for exemption. Informed consent was waived. Only Mayo Clinicpatients with research authorization were included.

As previously described<sup>17</sup>, eligible vax-plasma donors included individuals who had a confirmed 69 diagnosis of COVID-19 and had received at least one dose of a SARS-CoV-2 vaccine. All donors 70 71 experienced mild to moderate symptoms and met the national blood donor selection criteria. 72 Vax-plasma was collected at least 10 days and up to 6 months after the complete resolution of COVID-19 symptomatology. Antibody titers of vax-plasma units met the minimum threshold 73 required by the US FDA for high titer anti-SARS-CoV-2 antibodies, but precise antibody titers 74 were not evaluated. However, numerous reports indicate that vax-plasma is uniformly 75 extremely high titer with neutralizing activity against many SARS-CoV-2 variants<sup>10,13,18</sup>. The 76 77 treatment schedule of vax-plasma transfusions was not standardized. Patients received the 78 number of vax-plasma units deemed appropriate for each patient by their clinicians (range, 1 to 79 7 units).

80 The primary outcome was COVID-19–related hospitalization within 28 days after transfusion, 81 assessed as the cumulative incidence in the vax-plasma group compared to the standard of care group who declined treatment vax-plasma. The decision to hospitalize patients was at the 82 discretion of local clinicians. Continuous measures were compared between the treatment 83 groups (vax-plasma group vs. standard of care group) using the two-sample t-test, whereas 84 categorical measures were compared using the  $\chi^2$  test or Fisher exact test, as appropriate. 85 Reported p-values are two-sided and adjusted for multiplicity, as appropriate; and the 86 87 interpretation of findings was based on p < 0.05.

#### 88 **Results and discussion**

89 Three-hundred eighty-six immunocompromised patients were offered standard of care 90 treatments (e.g., remdesivir, nirmatrelyir or molnupiravir) and were also offered to be treated 91 with vax-plasma. Of those patients, 58% agreed to treatment with vax-plasma (225 of 386 92 patients; vax-plasma group) and 42% (161 of 386 patients) received standard of care 93 treatments alone without vax-plasma (standard of care group). Key demographic and clinical 94 characteristics of the study population are provided in **Table 1**, stratified into the two treatment 95 groups. Overall, the median age of all patients was 66 years (range: 2 to 96 years), 45% were 96 female (175 of 386 patients), and 94% (361 of 386 patients) were vaccinated against SARS-CoV-97 2.

- 98 Compared to patients in the standard of care group, patients in the vax-plasma group were
- 99 more likely to be female (*P*=0.038), more likely to have received anti-CD20 monoclonal therapy
- 100 (P=0.028), and more likely to have received previous COVID-19 antiviral treatments (P<0.001).
- 101 Other key differences between the groups are noted in **Table 1**.

Patients had COVID-19 symptoms for a median of 5 days (range, 1 to 46 days) before receiving 102 vax-plasma, and the median number of units transfused per patient was 1 (range, 1 to 7 units of 103 104 vax-plasma). Most patients (73%, 281 of 386 patients) agreed to receive concomitant COVID-105 19-specific treatments, and patients in the vax-plasma group were more likely to have received 106 COVID-19 specific treatments (88%, 198 of 225 patients) compared to the standard of care 107 group (52%, 83 of 161 patients; P<0.001). COVID-19 specific treatments included remdesivir 108 (65% of patients who accepted vax-plasma and 32% of those who declined vax-plasma), 109 nirmatrelvir and ritonavir (PAXLOVID<sup>™</sup>) (28% in the vax-plasma group and 20% in the standard 110 of care group), and/or molnupiravir (1% in the vax-plasma group and 4% in the standard of care 111 group).

112 No major adverse effects were recorded among patients transfused with vax-plasma. The 113 overall 28 day-hospital admission rate was 2.2% (5 of 225 patients) in vax-plasma group and 114 6.2% (10 of 161 patients) in standard of care group (*P*=0.046).

115 In this large, non-randomized cohort study involving outpatients with recent SARS-CoV-2 116 infection, the concomitant administration of high-titer COVID-19 convalescent plasma in addition to standard of care therapeutics was associated with a decreased incidence of 117 118 hospitalization. Our observations are consistent with those of previous trials of antibody-based 119 therapies — administration of sufficient pathogen-specific antibodies via COVID-19 convalescent 120 plasma leads to a reduced risk of disease progression, COVID-19-related hospitalization, and 121 COVID-19-related death in immunocompromised patients in both outpatient and inpatient settings.<sup>5,19</sup> Collectively, contemporary clinical data provide evidence to support the utility of 122 123 high-titer convalescent plasma including vax-plasma as antibody replacement therapy in immunocompromised patients.<sup>17,20,21</sup> 124

125 There is consensus that the primary mechanism of action of vax-plasma is through viral neutralization<sup>19</sup>—a finding established among humans early during the COVID-19 pandemic<sup>22</sup> 126 and supported by several preclinical models including mice,<sup>23,24</sup> hamsters,<sup>25</sup> and macaques.<sup>26</sup> 127 128 Because the neutralizing capacity of vax-plasma can evolve with emerging variants, issues 129 related to escape by new variants that have time limited the efficacy of monoclonal antibodies 130 can potentially be avoided. Additionally, sero-surveys of blood donors show a high prevalence of hybrid immunity in the population suggesting that very high titer vax-plasma is potentially 131 available at a scale sufficient to treat immunocompromised patients.<sup>27</sup> Thus, there is an 132 emerging picture of utility for vax-plasma therapy in immunocompromised patients with SARS-133 134 CoV-2 infection that could benefit from further evaluation via carefully matched, larger real 135 world data sets. Importantly, any prospective studies will need to consider the experimental 136 design and ethical issues associated with potentially limiting a safe antibody therapy in

immunocompromised patients unable to generate an adequate endogenous antibody responseto infection.

139 Our study faced several contextual challenges associated with clinical research during a pandemic and limitations associated with the design of the study. First, the interpretation of 140 these results is limited by the open-label and non-randomized design. In this framework, the 141 142 vax-plasma group had higher rates of anti-CD20 monoclonal therapy, antiviral COVID-19-143 specific therapeutics, and vaccination against SARS-CoV-2. Importantly, treatment with anti-144 CD20 monoclonal therapy among people who are immunosuppressed is associated with the lowest likelihood to produce SARS-CoV-2 antibodies after one or more doses of COVID-19 145 vaccines.<sup>16,28</sup> Thus, the effects of vax-plasma per se may not be definitively inferred. Second, the 146 147 overall incidence of hospitalization was very low (3.8%, 15 of 386 patients), likely due in part to 148 the very high number of patients who were vaccinated against SARS-CoV-2 and because most 149 patients received standard of care COVID-19-specific therapeutics. In this context, the low 150 incidence of the primary outcome (COVID-19-related hospitalization) limited the potential for 151 definitive subgroup analyses according to coexisting immunosuppressive conditions or other 152 putative confounding variables. Third, SARS-CoV-2 serology of vax-plasma units or patient 153 samples was not systematically performed.

154 Despite the enumerated limitations of this study, our data provides evidence that transfusion of 155 vax-plasma effectively transfers COVID-19-neutralizing antibodies to patients with 156 immunosuppression and reduces the risk of COVID-19-related hospitalization. Vax-plasma 157 appears to be an effective therapeutic throughout the clinical course of COVID-19 among 158 immunocompromised patients from outpatients to inpatients with protracted COVID-19. For 159 future pandemics, the use of therapeutic plasma with antibody levels in the upper deciles 160 should be considered, particularly among immunocompromised patients.

#### Acknowledgments

We thank the dedicated members of the Mayo Clinic Blood Donor Center for their rigorous efforts necessary to make this program possible. We also thank the donors who survived COVID-19 for providing vaccine-boosted COVID-19 convalescent plasma. Additionally, we thank Diana Zicklin Berrent and Chaim Lebovits for their progressive and passionate patient advocacy and support.

This work was supported by United Health Group and Mayo Clinic.

## Authorship Contributions

Study conception and design: J.G.R., S.M.T-S, M.J.J., and J.W.S. Acquisition, analysis, or interpretation of data: J.G.R., S.M.T-S, A.A.S., S.F., M.L.P., E.K.G., A.J.M., S.Z., E.A.O., and J.W.S. Drafting of the manuscript: J.G.R., S.M.T-S, M.J.J., and J.W.S. Administrative, technical, or material support: S.N.H., J.E.J., R.R.R., R.G., R.T.H., E.N.F., A.N.D., M.R.E., J.J.L., C.M.C., E.S.T., S.A.P., and N.E.K. All authors contributed to revising the manuscript, and all authors approved the final version of the manuscript.

### Disclosure of Conflicts of interest

The authors declare no conflict of interest.

#### Data Availability

Datasets generated during this study may be available from corresponding authors on reasonable request. Requestors may be required to sign a data use agreement. Data sharing must be compliant with all applicable Mayo Clinic policies and those of the Mayo Clinic Institutional Review Board.

#### ORCID

Juan G. Ripoll Shane Ford Ellen K. Gorman Justin E. Juskewitch Alexander J. Miller Solomiia Zaremba Erik A. Ovrom Raymund R. Razonable Ravindra Ganesh Elitza S. Theel Sameer A. Parikh Neil E. Kay Michael J. Joyner Jonathon W. Senefeld https://orcid.org/0000-0003-4908-9774 https://orcid.org/0000-0003-2776-9023 https://orcid.org/0000-0003-2989-547X https://orcid.org/0009-0006-2814-5561 https://orcid.org/0009-0006-3030-7232 https://orcid.org/0000-0002-5661-0698 https://orcid.org/0000-0002-5661-0698 https://orcid.org/0000-0001-5248-0227 https://orcid.org/0000-0002-6887-1712 https://orcid.org/0000-0002-6886-2294 https://orcid.org/0000-0002-3221-7314 https://orcid.org/0000-0002-5951-5055 https://orcid.org/0000-0002-7135-7643 https://orcid.org/0000-0001-8116-3538

### References

1. Fendler A, de Vries EGE, GeurtsvanKessel CH, et al. COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety. *Nat Rev Clin Oncol*. 2022;19(6):385-401.

2. Ribas A, Dhodapkar MV, Campbell KM, et al. How to Provide the Needed Protection from COVID-19 to Patients with Hematologic Malignancies. *Blood Cancer Discov*. 2021;2(6):562-567.

3. Taylor PC, Adams AC, Hufford MM, de la Torre I, Winthrop K, Gottlieb RL. Neutralizing monoclonal antibodies for treatment of COVID-19. *Nature Reviews Immunology*. 2021;21(6):382-393.

4. Shoham S, Batista C, Ben Amor Y, et al. Vaccines and therapeutics for immunocompromised patients with COVID-19. *eClinicalMedicine*. 2023;59:101965.

5. Senefeld JW, Franchini M, Mengoli C, et al. COVID-19 Convalescent Plasma for the Treatment of Immunocompromised Patients: A Systematic Review and Meta-analysis. *JAMA Netw Open*. 2023;6(1):e2250647.

6. Focosi D, McConnell S, Casadevall A, Cappello E, Valdiserra G, Tuccori M. Monoclonal antibody therapies against SARS-CoV-2. *Lancet Infect Dis*. 2022;22(11):e311-e326.

7. Focosi D, Maggi F, Franchini M, McConnell S, Casadevall A. Analysis of Immune Escape Variants from Antibody-Based Therapeutics against COVID-19: A Systematic Review. *Int J Mol Sci.* 2021;23(1).

8. VanBlargan LA, Errico JM, Halfmann PJ, et al. An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies. *Nat Med*. 2022;28(3):490-495.

9. Senefeld JW, Klassen SA, Ford SK, et al. Use of convalescent plasma in COVID-19 patients with immunosuppression. *Transfusion*. 2021;61(8):2503-2511.

10. Li M, Beck EJ, Laeyendecker O, et al. Convalescent plasma with a high level of virusspecific antibody effectively neutralizes SARS-CoV-2 variants of concern. *Blood Adv*. 2022;6(12):3678-3683.

11. Estcourt LJ, Cohn CS, Pagano MB, et al. Clinical Practice Guidelines From the Association for the Advancement of Blood and Biotherapies (AABB): COVID-19 Convalescent Plasma. *Ann Intern Med*. 2022;175(9):1310-1321.

12. Cesaro S, Ljungman P, Mikulska M, et al. Recommendations for the management of COVID-19 in patients with haematological malignancies or haematopoietic cell transplantation, from the 2021 European Conference on Infections in Leukaemia (ECIL 9). *Leukemia*. 2022;36(6):1467-1480.

13. Schmidt F, Weisblum Y, Rutkowska M, et al. High genetic barrier to SARS-CoV-2 polyclonal neutralizing antibody escape. *Nature*. 2021;600(7889):512-516.

14. Hueso T, Pouderoux C, Péré H, et al. Convalescent plasma therapy for B-cell-depleted patients with protracted COVID-19. *Blood*. 2020;136(20):2290-2295.

15. Thompson MA, Henderson JP, Shah PK, et al. Association of Convalescent Plasma Therapy With Survival in Patients With Hematologic Cancers and COVID-19. *JAMA Oncol*. 2021;7(8):1167-1175.

16. Greenberger LM, Saltzman LA, Senefeld JW, Johnson PW, DeGennaro LJ, Nichols GL. Antibody response to SARS-CoV-2 vaccines in patients with hematologic malignancies. *Cancer Cell*. 2021;39(8):1031-1033.

17. Ripoll JG, Gorman EK, Juskewitch JE, et al. Vaccine-boosted convalescent plasma therapy for patients with immunosuppression and COVID-19. *Blood Adv*. 2022;6(23):5951-5955.

18. Callaway E. COVID super-immunity: one of the pandemic's great puzzles. *Nature*. 2021;598(7881):393-394.

19. Casadevall A, Joyner MJ, Pirofski LA, et al. Convalescent plasma therapy in COVID-19: Unravelling the data using the principles of antibody therapy. *Expert Rev Respir Med.* 2023;17(5):381-395.

20. Senefeld JW, Joyner MJ. SARS-CoV-2 Antibody Replacement Therapy for Immunocompromised Patients. *Clin Infect Dis*. 2023.

21. Upasani V, Townsend K, Wu MY, et al. Commercial immunoglobulin products contain neutralising antibodies against SARS-CoV-2 spike protein. *Clin Infect Dis*. 2023.

22. Duan K, Liu B, Li C, et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. *Proc Natl Acad Sci U S A*. 2020;117(17):9490-9496.

23. Golden JW, Zeng X, Cline CR, et al. Human convalescent plasma protects K18-hACE2 mice against severe respiratory disease. *J Gen Virol*. 2021;102(5).

24. Zheng J, Wong LR, Li K, et al. COVID-19 treatments and pathogenesis including anosmia in K18-hACE2 mice. *Nature*. 2021;589(7843):603-607.

25. Haagmans BL, Noack D, Okba NMA, et al. SARS-CoV-2 Neutralizing Human Antibodies Protect Against Lower Respiratory Tract Disease in a Hamster Model. *J Infect Dis*. 2021;223(12):2020-2028.

26. McMahan K, Yu J, Mercado NB, et al. Correlates of protection against SARS-CoV-2 in rhesus macaques. *Nature*. 2021;590(7847):630-634.

27. Focosi D, Meschi S, Coen S, et al. Serum anti-Spike immunoglobulin G levels in random blood donors in Italy: High-titre convalescent plasma is easier than ever to procure. *Vox Sang*. 2023.

28. Pearce FA, Lim SH, Bythell M, et al. Antibody prevalence after three or more COVID-19 vaccine doses in individuals who are immunosuppressed in the UK: a cross-sectional study from MELODY. *Lancet Rheumatol.* 2023;5(8):e461-e473.

# Table 1. Characteristics of 386 immunocompromised outpatients who were diagnosed with COVID-19 and received standard of care COVID-19 therapeutics with or without vax-plasma.

	Vax-plasma, N = 225	SOC, N = 161	<i>P</i> value
Demographic information			
Age, median (range), years	66 (2-93)	64 (20-96)	0.468
Females/males, n	112/113	63/98	0.038
Height, median (range), cm	172.5 (85.3-195.0)	173.0 (146.2-197.4)	0.440
Weight, median (range), kg	82.7 (12.4-176.0)	81.5 (44.6-210.0)	0.691
Body Mass Index, median (range), kg·m <sup>-2</sup>	28.1 (17.0-54.1)	27.6 (18.2-63.7)	0.952
Hematological malignancies, n (%)			
Multiple Myeloma	30 (13)	38 (24)	0.009
Chronic lymphocytic leukemia	43 (19)	20 (12)	0.080
Diffuse large B-cell lymphoma	20 (9)	23 (14)	0.097
Follicular lymphoma	15 (7)	4 (2)	0.061
Other malignancy <sup>a</sup>	57 (25)	45 (28)	0.331
Other immunosuppressive conditions, n (%)			
Multiple sclerosis	25 (11)	6 (4)	0.008
Solid organ transplant <sup>b</sup>	13 (6)	13 (8)	0.375
Common variable immune deficiency	3 (1)	5 (3)	0.228
Granulomatosis with Polyangiitis	5 (2)	4 (2)	0.866
Other immunosuppressive conditions <sup>c</sup>	17 (8)	9 (6)	0.447
Active immunosuppressive treatment, n (%)			
Anti-CD20 therapy	78 (35)	39 (24)	0.028
Anti-CD38 therapy	15 (7)	11 (7)	0.949
Bruton tyrosine kinase inhibitors	22 (10)	11 (7)	0.307
Previous COVID-19-specific treatments, n (%)	198 (88)	83 (52)	<0.001
Remdesivir	146 (65)	52 (32)	<0.001
Paxlovid	62 (28)	33 (20)	0.112
Molnupiravir	3 (1)	6 (4)	0.124
Vaccinated against SARS-CoV-2, n (%)	214 (95)	147 (91)	0.134
Number of SARS-CoV-2 vaccines <sup>d</sup> , mean (SD), n	3.8 (1.6)	3.7 (1.2)	0.504
Units of vax-plasma, median (range), n	1 (1-7)		
Time to treatment, median (range), days	5 (1-46)		
Hospital admission, n (%)	5 (2.2)	10 (6.2)	0.046

Footnotes

Note that hematological malignancies and other immunosuppressive conditions are not mutually exclusive.

<sup>a</sup>Other malignancies included acute lymphoblastic leukemia (ALL, n = 5); acute myeloid leukemia (AML, n = 7); anaplastic large cell lymphoma (N = 1); angioimmunoblastic T-cell Lymphoma (n = 1); chronic lymphoproliferative disorder of natural killer cells (CLPD-NK, n = 1); chronic myeloid leukemia (CML, n = 8); chronic myelomonocytic leukemia (CMML, n = 1); cutaneous B-cell lymphoma (n = 1)Dermatomyositis (n = 1); duodenal adenocarcinoma (n = 1); gastroesophageal junction adenocarcinoma (n = 1); Hairy Cell Leukemia (n = 1); hodgkin lymphoma (HL, n = 11); large granular lymphocytic leukemia (n = 1); lung adenocarcinoma (n = 3);MALT Lymphoma (n = 2); mantle cell lymphoma (MCL, n = 8); marginal zone lymphoma (MZL, n = 12); Metastatic Carcinoid Tumor (n = 1); Metastatic Melanoma (n = 1); monoclonal gammopathy of undetermined significance (MGUS, n = 5); myelodysplastic syndrome (MDS, n = 8); Myelofibrosis (n = 1); Polycythemia Vera (n = 2); Prolymphocytic Leukemia (n = 1); Testicular Cancer (n = 1); non-Hodgkin lymphoma (n = 1), and small lymphocytic lymphoma (n = 1); Waldenstrom macroglobulinemia (WM, n = 16).

<sup>b</sup>Solid organ transplants included: kidney (n = 3); heart (n = 1); kidney and pancreas (n = 4); lung(s) (n = 11); lung and heart (n = 1); kidney and liver (n = 2); kidney and heart (n = 3); and heart, liver, and kidney (n = 1).

<sup>c</sup>Other immunosuppressive conditions included: autoimmune lymphoproliferative syndrome (ALPS, n = 1); Amyloidosis (n = 2); ANCA Vasculitis (n = 2); autoimmune myositis (n = 2); HIV (n = 2); Immune Thrombocytopenic Purpura (ITP, n = 1); membranous nephropathy (MN, n = 1); minimal change disease (n = 1); Neuromyelitis Optica (n = 1); Rheumatoid Arthritis (RA, n = 6); Stiff-Person Syndrome (SPS, n = 1); systemic lupus erythematosus (SLE, n = 3); thrombotic thrombocytopenic purpura (TTP, n = 1); undifferented primary immunodeficiency (n = 1); and a constellation of comorbidities (seizure disorder, previous stroke, ventricular septal defect, prolonged QT interval, right bundle-branch block, congestive heart failure, chronic obstructive pulmonary disease; n = 1).

<sup>d</sup>The mean number of SARS-CoV-2 vaccines was calculated among people who have been vaccinated against SARS-CoV-2, including 214 patients in the vax-plasma group and 147 patients in the standard of care (SOC) group.